Lexaria Bioscience Management

Management criteria checks 4/4

Lexaria Bioscience's CEO is Chris Bunka, appointed in Feb 2007, has a tenure of 17.25 years. directly owns 2.12% of the company’s shares, worth $861.66K. The average tenure of the management team and the board of directors is 9.1 years and 8.1 years respectively.

Key information

Chris Bunka

Chief executive officer

US$291.2k

Total compensation

CEO salary percentage	n/a
CEO tenure	17.3yrs
CEO ownership	2.1%
Management average tenure	9.1yrs
Board average tenure	8.1yrs

Recent management updates

Recent updates

Lexaria Bioscience gets third patent granted in Japan

Jul 14

Lexaria Bioscience's DehydraTECH licensee Cannadips expands internationally

Jul 07

Is Lexaria Bioscience (NASDAQ:LEXX) In A Good Position To Deliver On Growth Plans?

Apr 15

We Think Lexaria Bioscience (NASDAQ:LEXX) Can Afford To Drive Business Growth

Dec 07

Lexaria Hits New 52-Week High With Positive Data On Enhanced Treatment For COVID-19

Jul 22

CEO

Chris Bunka (61 yo)

17.3yrs

Tenure

US$291,193

Compensation

Mr. Christopher A. Bunka, also known as Chris, serves as the Chairman, Chief Executive Officer, President and Secretary of Drift Capital Corp. Mr. Bunka serves as the President and a Director of CAB Financ...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Christopher Bunka	Chairman & CEO	17.3yrs	US$291.19k	2.12% $ 861.7k
John Docherty	President & Director	9.1yrs	US$290.47k	0% $ 0
Nelson Cabatuan	Chief Financial Officer	less than a year	no data	no data
Kristin Hamilton	Director of Operations	no data	no data	no data
Vanessa Carle	Head of Legal	no data	no data	0.020% $ 8.1k
Philip Ainslie	Advisor & Consultant	no data	no data	no data

9.1yrs

Average Tenure

54yo

Average Age

Experienced Management: LEXX's management team is seasoned and experienced (9.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Christopher Bunka	Chairman & CEO	17.6yrs	US$291.19k	2.12% $ 861.7k
John Docherty	President & Director	8.1yrs	US$290.47k	0% $ 0
Philip Ainslie	Advisor & Consultant	no data	no data	no data
Albert Reese	Independent Director	3.3yrs	US$54.78k	0.085% $ 34.4k
Nicholas Baxter	Independent Director	12.8yrs	US$80.75k	0.085% $ 34.7k
William McKechnie	Independent Director	8.7yrs	US$72.04k	0.10% $ 41.6k
Julian Gangolli	Strategic Advisor	1.3yrs	no data	no data
Catherine Turkel	Independent Director	1.7yrs	US$48.92k	0.012% $ 4.7k

8.1yrs

Average Tenure

65yo

Average Age

Experienced Board: LEXX's board of directors are considered experienced (8.1 years average tenure).

Lexaria Bioscience Management

Management criteria checks 4/4

Key information

Recent management updates

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Lexaria Bioscience Corp., Annual General Meeting, Apr 23, 2024

Lexaria Bioscience Corp. Announces Chief Financial Officer Changes

Lexaria Bioscience Corp. Appoints Julian Gangolli as Strategic Advisor

Lexaria Bioscience Corp. Appoints Dr. Catherine Turkel to its Board of Directors

High number of new directors

Recent updates

Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study

Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study

Consensus revenue estimates increase by 24%

Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study

Second quarter 2024 earnings released: US$0.06 loss per share (vs US$0.22 loss in 2Q 2023)

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Lexaria Bioscience Corp., Annual General Meeting, Apr 23, 2024

Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1

Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. Submits Investigational New Drug Application

Consensus revenue estimates increase by 100%

Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program

First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.29 loss in 1Q 2023)

Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform

Lexaria Bioscience Corp. Announces Positive Final Results from its Recently Completed Human Pilot Study #1 for the Oral Performance of the Rybelsus(R)-Branded GLP-1 Drug Semaglutide

Lexaria Bioscience Corp. Announces Investigational New Drug Application Filing Update

Consensus revenue estimates decrease by 20%, EPS upgraded

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Full year 2023 earnings: EPS and revenues miss analyst expectations

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $0.114546 million.

Lexaria Bioscience Corp. Evaluates Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

Lexaria Bioscience Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Lexaria Bioscience Corp. Announces Its Intention to Launch New Human and Animal Studies to Examine Dehydratech™-Processed Glucagon-Like Peptide-1

Lexaria Bioscience Corp. Provides Update on Investigational New Drug Application Progress

Consensus revenue estimates increase by 38%, EPS downgraded

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD

Lexaria Bioscience Corp Grants Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products

New major risk - Revenue and earnings growth

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

Lexaria Bioscience Receives Nasdaq Bid Price Deficiency Notice

Lexaria's DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study

Lexaria Bioscience Corp. Announces Chief Financial Officer Changes

Lexaria Bioscience Corp. Discovers That DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers

Lexaria Bioscience Corp. Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery

Lexaria Bioscience Corp. Announces Batch Manufacturing of the DehydraTECH™-Processed Cannabidiol

Lexaria Bioscience Corp. has completed a Composite Units Offering in the amount of $2.0007 million.

Lexaria Bioscience Corp. has completed a Composite Units Offering.

Lexaria Bioscience Corp. Human Clinical Nicotine Study Completes Dosing as Planned

Consensus revenue estimates fall by 65%

Second quarter 2023 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2022)

Lexaria Bioscience Corp. Appoints Julian Gangolli as Strategic Advisor

First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.35 loss in 1Q 2022)

Lexaria Bioscience Corp.'s DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels

Lexaria Bioscience Corp. Human Oral Nicotine Study Begins Dosing

Lexaria Bioscience Corp. Enhances Performance Compared to Epidiolex in Seizure Study Program

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$15.00

Lexaria Bioscience Corp. Announces Examining Potential Therapeutic Use of Dehydratech-Cbd in Dementia

Lexaria Bioscience Corp. Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes

Lexaria Receives Independent Review Board Approval for Its Upcoming Human Oral Nicotine Study

Lexaria Bioscience Corp. Announces That Human Clinical Study Hyper-H21-4 the Worlds First Study to Evidence A Sustained Drop in Bp in Normally Active Hypertensive Patients

Lexaria Bioscience Corp. Appoints Dr. Catherine Turkel to its Board of Directors

Lexaria Bioscience Corp. Receives Positive Full Written Response from the Food and Drug Administration from Its Pre-Investigational New Drug

Consensus EPS estimates fall by 11%

Lexaria Bioscience Corp. Announces Dosing with Lexaria's DehydraTECH-Processed Cannabidiol Is Completed

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Lexaria Bioscience Corp. Announces That It Has Been Notified of the Allowance of Its 26Th Worldwide Patent with A New Patent to Be Granted in Japan

Lexaria Bioscience Corp. Announces the Pending Start of Its Upcoming Human Nicotine Study Nic-H22-1

Lexaria Bioscience gets third patent granted in Japan

Lexaria Bioscience's DehydraTECH licensee Cannadips expands internationally